Development and in vitro evaluation of core–shell type lipid–polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer
B Mandal, NK Mittal, P Balabathula, LA Thoma… - European journal of …, 2016 - Elsevier
Core–shell type lipid–polymer hybrid nanoparticles (CSLPHNPs) have emerged as a
multifunctional drug delivery platform. The delivery system combines mechanical …
multifunctional drug delivery platform. The delivery system combines mechanical …
[HTML][HTML] Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid …
J Pang, H Xing, Y Sun, S Feng, S Wang - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in
China. This study aimed to develop a hyaluronic acid (HA) decorated, pH sensitive lipid …
China. This study aimed to develop a hyaluronic acid (HA) decorated, pH sensitive lipid …
Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer
Non-small cell lung cancer (NSCLC) patients with sensitizing mutations in the exons 18–21
of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR …
of the epithelial growth factor receptor (EGFR) gene show increased kinase activity of EGFR …
PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer
In this study, a core-shell type polypeptide-based lipid nanocapsule was developed to
enhance anticancer efficacy of erlotinib in non-small cell lung cancers. Mean particle size of …
enhance anticancer efficacy of erlotinib in non-small cell lung cancers. Mean particle size of …
[HTML][HTML] Comparative of in-vitro evaluation between erlotinib loaded nanostructured lipid carriers and liposomes against A549 lung cancer cell line
FA Gaballu, S Abbaspour-Ravasjani… - Iranian journal of …, 2019 - ncbi.nlm.nih.gov
Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in
gastrointestinal environment, has been considered as a therapeutic agent for Non-Small …
gastrointestinal environment, has been considered as a therapeutic agent for Non-Small …
Role of solid lipid nanoparticles as drug delivery vehicles on the pharmacokinetic variability of Erlotinib HCl
R Rampaka, K Ommi, N Chella - Journal of Drug Delivery Science and …, 2021 - Elsevier
Abstract Background and objectives Erlotinib HCl is approved for the treatment of metastatic
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …
Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer
This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …
[HTML][HTML] Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid …
Z Song, Y Shi, Q Han, G Dai - Biomedicine & Pharmacotherapy, 2018 - Elsevier
Special targeted therapy like endothelial growth factor receptor (EGFR) targeted therapy is
available for the treatment of advanced non-small cell lung cancer (NSCLC). Biodegradable …
available for the treatment of advanced non-small cell lung cancer (NSCLC). Biodegradable …
Microfluidic fabrication and characterization of Sorafenib-loaded lipid-polymer hybrid nanoparticles for controlled drug delivery
Lipid polymer hybrid nanoparticles (LPHNPs) have been merged as potential nanocarriers
for treatment of cancer. In the present study, LPHNPs loaded with Sorafenib (SFN) were …
for treatment of cancer. In the present study, LPHNPs loaded with Sorafenib (SFN) were …
HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment
Y Shen, W Li - Drug design, development and therapy, 2018 - Taylor & Francis
Background Aim of this study was to prepare the hyaluronic acid and human serum albumin
modified erlotinib nanoparticles (ERT-HSA-HA NPs) delivery system by a precipitation …
modified erlotinib nanoparticles (ERT-HSA-HA NPs) delivery system by a precipitation …
相关搜索
- lipid polymer hybrid nanoparticles
- lipid polymer delivery of erlotinib
- hybrid nanoparticles delivery of erlotinib
- combination therapy delivery of erlotinib
- lipid polymer combination therapy
- hybrid nanoparticles combination therapy
- lipid polymer docetaxel and resveratrol
- lipid polymer microfluidic fabrication
- hyaluronic acid delivery of erlotinib
- hybrid nanoparticles docetaxel and resveratrol
- hybrid nanoparticles microfluidic fabrication
- lipid polymer hyaluronic acid
- hybrid nanoparticles hyaluronic acid
- lung cancer nuclear egfr
- lipid polymer growth factor
- hybrid nanoparticles growth factor